<style type="text/css">body .wpex-vc-row-stretched, body .vc_row-o-full-height { visibility: visible; }</style> skip to Main Content

News

Galmed Pharmaceuticals to Report Third Quarter 2018 Financial Results and Provide Business Update on Monday, November 5

TEL AVIV, Israel, Oct. 29, 2018 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmedˮ or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the liver targeted SCD1 modulator Aramchol™, a once-daily, oral therapy for the treatment of nonalcoholic steatohepatitis ("NASH"), announced today that it will host a conference call and webcast on Monday, November 5, 2018, to provide an update on current developments with respect to its clinical programs for Aramchol™ and to discuss financial results for the three and nine  months ended September 30, 2018.

Galmed Pharmaceuticals logo

Conference Call & Webcast:



Monday, November 5 @ 8:30am Eastern Time


Within the US:                       

800-239-9838 

Outside the US:                     

323-794-2551

From Israel:                            

1809 212 883

Conference ID:                       

9320949

Webcast:                               

http://public.viavid.com/index.php?id=131686



Replays, Available through November 19:      


Domestic:                               

844-512-2921

International:                          

412-317-6671

Replay PIN:                            

9320949

About Galmed Pharmaceuticals Ltd.

Galmed is a clinical-stage biopharmaceutical company focused on the development of Aramchol, a first in class, novel, once-daily, oral therapy for the treatment of NASH for variable populations. Galmed recently announced top-line results of the ARREST Study, a multicenter, randomized, double blind, placebo-controlled Phase IIb clinical study designed to evaluate the efficacy and safety of Aramchol in subjects with NASH, who are overweight or obese, and who are pre-diabetic or type-II-diabetic. Galmed is currently preparing for an end of Phase IIb meeting with the FDA to discuss the results of the ARREST Study and a Phase III study protocol, with a view to initiating a Phase III clinical study of Aramchol in 2019.

 

SOURCE Galmed Pharmaceuticals Ltd.

For further information: Timothy McCarthy, LifeSci Advisors, LLC, +1-212-915-2564, tim@lifesciadvisors.com Guy Nehemya, VP Operations, Galmed Pharmaceuticals Ltd., guy@galmedpharma.com
Back To Top